ELEFTHA 440MG

Product Description

It appears there might be a slight typo in your inquiry. The medication you're referring to is likely "Trastuzumab" rather than "Tastuzumab." Trastuzumab is a monoclonal antibody used in the treatment of certain types of cancer, particularly HER2-positive breast cancer and HER2-positive gastric or gastroesophageal junction (GEJ) cancer.

Trastuzumab is typically administered intravenously. The dosage can vary depending on factors such as the type and stage of cancer, as well as individual patient factors. The standard dose for trastuzumab in HER2-positive breast cancer is typically given as an initial loading dose followed by maintenance doses.

For HER2-positive breast cancer, the loading dose is usually 8 mg/kg followed by subsequent doses of 6 mg/kg every three weeks. For HER2-positive gastric or GEJ cancer, the dosage and schedule may vary.

The dosage you provided, "440 mg," may represent the total amount of trastuzumab in a vial or container. However, the specific dosage and administration schedule should be determined by a healthcare professional based on the patient's individual condition and treatment plan.

Trastuzumab works by targeting the HER2 protein, which is overexpressed in certain cancer cells, inhibiting their growth and proliferation. It is often used in combination with other cancer treatments such as chemotherapy.

As with any medication, trastuzumab may cause side effects, which can vary from person to person. Common side effects may include infusion reactions, cardiotoxicity (heart problems), nausea, diarrhea, fatigue, and others.

If you have any further questions or concerns about trastuzumab or its usage, it's important to consult with a healthcare professional for personalized medical advice and guidance.